Bicara Therapeutics Inc. (BCAX) vs Ultragenyx Pharmaceutical Inc. (RARE)

Bicara Therapeutics Inc. and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. Bicara Therapeutics Inc. and Ultragenyx Pharmaceutical Inc. are of similar size ($1.5B and $1.3B). Bicara Therapeutics Inc. has the higher net margin (0.00% vs −81.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 10 metrics below, Bicara Therapeutics Inc. leads on 8 and Ultragenyx Pharmaceutical Inc. on 2.

Valuation

Metric BCAX RARE Biotechnology median
P/E n/m n/m 7.88
P/S n/m 2.06 11.47
P/B 2.78 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 1.65 10.73
Earnings yield (16.14%) (40.28%) (28.84%)
Free cash flow yield (10.36%) (33.43%) (23.03%)

Profitability

Metric BCAX RARE Biotechnology median
Gross margin — 83.12% 65.16%
Operating margin 0.00% (73.64%) 0.00%
Net margin 0.00% (81.73%) 0.00%
Free cash flow margin 0.00% (68.90%) 0.00%
Return on equity (41.01%) 838.86% (57.72%)
Return on assets (38.38%) (45.60%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BCAX RARE Biotechnology median
Revenue growth (TTM) — 17.51% 5.64%
EPS growth (last fiscal year) 37.78% 7.31% —
Revenue growth, 5-year CAGR — 19.95% 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BCAX RARE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.59 1.73 4.73
Net debt to EBITDA 2.67 1.35 0.96

Dividend

Metric BCAX RARE Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric BCAX RARE Biotechnology median
Market cap 1.32b 1.45b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack